Relay Therapeutics Business Summary

Relay Therapeutics, Inc. (RLAY) is a clinical-stage precision medicine company that generates revenue primarily through strategic collaboration and license agreements, most notably with Genentech and D.E. Shaw Research. The company’s business model is built upon its proprietary Dynamo platform, which integrates advanced computational modeling with structural biology to drug previously intractable protein targets by analyzing their dynamic motion. Its primary business segments are focused on targeted oncology and genetic diseases, with lead clinical assets including zovegalisib (RLY-2608), a pan-mutant selective PI3Kα inhibitor that recently received FDA Breakthrough Therapy designation, and RLY-4008, a selective FGFR2 inhibitor. Within the competitive landscape, Relay contends with precision medicine peers such as Kymera Therapeutics, Cogent Biosciences, and Revolution Medicines; it distinguishes itself by focusing on motion-based drug design rather than static protein structures, positioning it as a leader in the next generation of structure-based drug discovery. The company was founded in 2016 by a high-pedigree team including David E. Shaw (founder of D. E. Shaw Research), Matt Jacobson, Mark Murcko, Dorothee Kern, and founding investor Alexis Borisy, who currently serves as Chairman of the Board. The executive leadership team is led by President and CEO Dr. Sanjiv K. Patel, formerly an Executive Vice President at Allergan, alongside Dr. Don Bergstrom (President of R&D), Tom Catinazzo (CFO), and Dr. Jim Watters (CSO). The company’s technical and scientific depth is further bolstered by Senior Advisor Dr. Pat Walters, a pioneer in computational chemistry. Relay is backed by a robust roster of institutional investors, including Third Rock Ventures, SoftBank (Svf Pauling Cayman Ltd), Casdin Capital, and GV (Google Ventures), maintaining a significant cash runway to fund operations through major clinical milestones in late 2026.